Eagle Pharmaceuticals (EGRX) Reports Tough 3Q Results; Piper Jaffray Cuts Price target to $97
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Eagle Pharmaceuticals to Present at November Conferences
November 12, 2015 7:00 AM ESTWOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) announced today that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will each present at two conferences in November as follows:
    Stifel 2015 Healthcare Conference      Presenter: David Riggs  ... MoreEagle Pharmaceuticals, Inc. Reports Third Quarter 2015 Results
November 11, 2015 7:00 AM ESTWOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq: EGRX) today announced its financial results for the three- and nine-month periods ended September 30, 2015. Highlights of and subsequent to the third quarter of 2015 include:
Entered into a co-promotion agreement with Spectrum Pharmaceuticals, under which Spectrums 32-person Corporate Accounts Sales Team, focused in the hematology and oncology space, will dedicate 80% of its time to marketing up to six Eagle products over the next 18 months. The agreement facilitates Eagles transition into a fully-commercial pharmaceutical company with limited... More